AstraZeneca amends license deal with Chinese biotech; Chinese protein-based vaccine gets manufacturing OK
In an effort to boost the supply of its AAV Covid-19 vaccine abroad, AstraZeneca has amended its license agreement with Biokangtai to commercialize the drug in mainland China, Pakistan and Indonesia, Biokangtai announced Wednesday.
Biokangtai will market, manufacture and distribute the drug to ease the shortened supply and make the vaccine more accessible. The vaccine has been approved in 185 countries so far, the company said in a press release, but shortened supply, coupled with issues surrounding rare, but fatal, blood clots, have led vaccination numbers to stall out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.